16 December 2025
Latham & Watkins Represents Vera Therapeutics in US$300 Million Offering of Common Stock
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Keith Halverstam Lead | Latham & Watkins LLP | Partner | Capital Markets | Not stated |
| Elisabeth Martin Lead | Latham & Watkins LLP | Partner | Capital Markets | Not stated |
| Amanda Farrish | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Jessica Kerr | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Chanie Saltzman | Latham & Watkins LLP | Not stated | Not stated | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | FDA matters | Not stated |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA matters | Not stated |
| Evan Miller | Latham & Watkins LLP | Associate | FDA matters | Not stated |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare matters | Not stated |
| Katharine Moir | Latham & Watkins LLP | Partner | tax matters | Not stated |
| Dennis Poehland | Latham & Watkins LLP | Associate | tax matters | Not stated |
| Emily Corbi | Latham & Watkins LLP | Counsel | public company representation matters | Not stated |
Stated terms
- Stated value
- USD 300m (US$300 million)
- What the figure measures
- Issue size
- Client
- Vera Therapeutics, Inc.Issuer
- Counterparties
- Not stated